- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pentixapharm Holding AG (PTPn)
Pentixapharm Holding AG stock price live, this page displays ETR PTPn stock exchange data. View the PTPn premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Pentixapharm Holding AG real time stock price chart below.
What Is the Pentixapharm Holding AG Stock Price Today?
The Pentixapharm Holding AG stock price today is 2.04.
What Is the Stock Symbol for Pentixapharm Holding AG?
The stock symbol for Pentixapharm Holding AG is "PTPn."
What Stock Exchange Does Pentixapharm Holding AG Trade On?
Pentixapharm Holding AG is listed and trades on the Xetra stock exchange.
Is Pentixapharm Holding AG a Good Stock to Buy?
Determining whether Pentixapharm Holding AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PTPn quote. (ISIN: DE000A40AEG0)
What Is the Pentixapharm Holding AG Stock Price Today?
The Pentixapharm Holding AG stock price today is 2.04.
What Is the Stock Symbol for Pentixapharm Holding AG?
The stock symbol for Pentixapharm Holding AG is "PTPn."
What Stock Exchange Does Pentixapharm Holding AG Trade On?
Pentixapharm Holding AG is listed and trades on the Xetra stock exchange.
Is Pentixapharm Holding AG a Good Stock to Buy?
Determining whether Pentixapharm Holding AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PTPn quote. (ISIN: DE000A40AEG0)
2.04
-0.14(-6.42%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.03
2.06
52 wk Range
1.30
3.70
PTPn is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.032.06
52 wk Range
1.303.70
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
PTPn Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
12.61
Upside
+518.14%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Pentixapharm's Ga68-PentixaFor wins EMA PRIME status
- Investing.com
- Pentixapharm's Ga68-PentixaFor wins EMA PRIME status
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 12.61
(+518.14% Upside)
Earnings
Latest Release
May 07, 2026
EPS / Forecast
-0.13 / --
Revenue / Forecast
59K / --
Compare PTPn to Peers and Sector
Metrics to compare | PTPn | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPTPnPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.4x | 2.9x | −0.4x | |
PEG Ratio | −3.30 | −0.09 | 0.00 | |
Price/Book | 1.7x | 1.9x | 2.6x | |
Price / LTM Sales | 136.1x | 1.7x | 3.0x | |
Upside (Analyst Target) | - | 34.7% | 51.5% | |
Fair Value Upside | Unlock | 15.1% | 8.8% | Unlock |
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase 1/2 study; and develops diagnosis for functional adrenal tumors, which is in Phase II study. It also develops anti-GlycoTarget antibodies to treat solid tumors. In addition, the company’s PentixaFor is being developed as a diagnostic tool for primary hypertension, a cause of hypertension, which is in Phase III trial. Further, its pipeline products for oncology indications include PT-00X, GT-00X, GT-001, GT-002, GT-005, and GT-008. Pentixapharm Holding AG was founded in 2019 and is based in Berlin, Germany.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Pentixapharm Holding (PTPn) Stock Price Today?
The Pentixapharm Holding stock price today is 2.04 EUR.
What Stock Exchange Does Pentixapharm Holding Trade On?
Pentixapharm Holding is listed and trades on the Frankfurt Stock Exchange.
What Is the Stock Symbol for Pentixapharm Holding?
The stock symbol for Pentixapharm Holding is "PTPn."
What Is the Pentixapharm Holding Market Cap?
As of today, Pentixapharm Holding market cap is 54.03M EUR.
What Is Pentixapharm Holding's Earnings Per Share (TTM)?
The Pentixapharm Holding EPS (TTM) is -0.64.
From a Technical Analysis Perspective, Is PTPn a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Pentixapharm Holding Stock Split?
Pentixapharm Holding has split 0 times.
How Many Employees Does Pentixapharm Holding Have?
Pentixapharm Holding has 36 employees.
What is the current trading status of Pentixapharm Holding (PTPn)?
As of Jul 13, 2026, Pentixapharm Holding (PTPn) is trading at a price of 2.04 EUR, with a previous close of 2.18 EUR. The stock has fluctuated within a day range of 2.03 EUR to 2.06 EUR, while its 52-week range spans from 1.30 EUR to 3.70 EUR.
What Is Pentixapharm Holding (PTPn) Price Target According to Analysts?
The average 12-month price target for Pentixapharm Holding is 12.61 EUR, with a high estimate of 12.61 EUR and a low estimate of 12.61 EUR. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +518.14% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.